Key Drivers
- Strong liquidity
- Severe cash burn
- Minimal revenue
AIAI Summary
CRNX has shifted from a binary R&D gamble to an early commercial-stage story—early PALSONIFY revenue and a ~$1.03B cash runway materially de‑risk near‑term financing but the investment now hinges on flawless commercialization (payer access, prescriber adoption) and whether revenue can scale fast enough to offset very high cash burn and avoid further dilution.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •Severe cash burn
- •Minimal revenue
CRNX has a strong balance sheet and high gross margins but is undermined by minimal revenue, heavy operating losses and negative cash flow that make its current valuation unjustified.
Price Behavior
Key Price Behavior Insights:
- •Downside momentum
- •Defined short-term floor
- •Resistance cluster
CRNX is in a clear short-term downtrend—down ~18% from $43.44 to $35.57 over the last month, trading ~9.6% below its 21-day average (~$39.4) with immediate support near $35.50–$36.10 and resistance at $38.20–$39.50 (stronger near $44.50).
Price fell ~18% from $43.44 to $35.57 over the last month, signaling elevated downside risk
Sentiment & News
Key News Insights:
- •PALSONIFY revenue
- •GPCR pipeline
- •Investor sell-down
Crinetics posted a smaller-than-expected Q4 loss while PALSONIFY generated $5.4M in Q4 revenue with early U.S. uptake, the company reiterated GPCR-focused pipeline progress and an upcoming EU milestone amid investor repositioning.
Early commercial revenue and regulatory progress support the company's growth thesis and could lift sentiment, but investor selling signals continued near-term caution
Similar Companies in Healthcare
Other companies in the same sector with AI ratings